Sphere Fluidics

Year founded 2010
HQ Location Cambridge
Sector Medical Technology
Staff count 26
Turnover (2017) £1.5m
Sphere Fluidics makes cell-analysis systems to help pharmaceutical companies discover new potential blockbusters, and has raised more than £16m of financial capital and grants in eight years.
www.spherefluidics.com
Don't be afraid to change your business model and if you can move to greater profitability you should do it.

Frank Craig

CEO

Changing a business model reaps rewards

Sphere Fluidics is disrupting how the pharmaceutical industry discovers commercially viable biomolecules. Its flagship product, the Cyto-Mine® platform, performs a number of cellular processes that would usually require several types of equipment and cost twice as much.

Initially, the company planned to provide its product as a service to drug companies’ hungry R&D departments. “Our original vision was to run a biopharmaceutical discovery service. It would’ve been straightforward and we wouldn’t have had to raise big money,” says CEO Frank Craig.

However, the issue Craig had with this model was the lack of scalability. “It can take 12 months to sell one contract,” he says.

It would have taken years and cost about £40 million to build our own factory, but we were able to leverage external partnerships and get the product to market fast.

Frank Craig, Sphere Fluidics

 

When tech partnered with manufacturing

The real growth potential was in manufacturing and selling the product’s units. “We couldn’t sell 200 services a year, but we could sell 200 machines.” says Craig.

Craig then convinced the company’s board to fund research into how receptive the market would be to purchasing units. The results came back very positive, so soon they embarked on a plan to start manufacturing the high-value machines.

However, he knew they would need help from technology and manufacturing partners.

“We partnered with various external system design companies, software companies, and manufacturers that were best in their field in the UK and Europe,” says Craig.

“It would have taken years and cost about £40m to build our own factory, but we were able to leverage external partnerships and get the product to market fast,” he says.

 

Partners in growth

Building partnerships is the secret to the company’s scaling. “Partnerships allowed us to scale. Sure, there were some stresses like partners don’t always give you what they promise, but if we did everything internally, we’d have had too many limitations,” says Craig.

The company approached investment in much the same way, finding the right investment partners. It has secured £11m in equity funding, a £2m convertible loan and about £3.1m of grants.

“We’ve been lucky to be able to pick some really good grant partners,” says Craig. Glaxosmithkline, Horizon Discovery, UCB and Imperial College London have been particularly supportive, he says.

 

Looking to the future

To date the company has sold its product in the EU, Asia and the US. And its ambition is to sell to more than 500 customers all over the world. Each unit costs $450,000.

Craig’s strategic pivot into sales and manufacturing has paid off, with the company’s income expected to grow by around 300% this year.

With a planned turnover of £6m this financial year, the company is looking to invest in rolling out a second flagship product, a desktop genome-editing machine. It will cost “around £10m” to build, but Craig believes there is a global market worth several hundred million pounds.

Right now the company is looking for investment to support the rollout of this new product. Craig has his sights abroad: “It would be strategically beneficial to source investment from the US for the next round as we’re always thinking internationally.”


Key Metrics

+300%

Planned turnover growth

25

Different Products Commercialised

55%/45%

Domestic/international sales

Sources of capital
Supported By

Related Stories

Rachel Jackson London
In 10 years Rachel Jackson has turned her market stall into a celebrity-endorsed jewellery brand with a £1m turnover, but the demands of a growing company have forced the mum-of-two to constantly re-evaluate her role. Read more...
VoxSmart
VoxSmart revamped its ailing brand with a healthy injection of technology, smart market positioning and human capital, increasing the team tenfold to 35+ staff and generating a healthy £2m in turnover. Read more...
Sumdog
Raising capital to fund its social impact mission has been a journey of discovery for Sumdog, and the online education specialist believes that human capital drives its ability to make the financials add up. Read more...
busuu
Founder and CEO Bernhard Niesner says that having the wrong culture created a “near-death experience” for busuu, but a concerted turnaround has put the mobile language-learning platform at the top of its class for the past few years. Read more...
Upper Street
Upper Street CEO and co-founder Julia Elliott Brown explains her tough decision to fold her fashion tech company came after an unforeseen funding crunch put a halt to its six-year scale-up journey. Read more...
Redington
Redington’s co-founders, Robert Gardner and Dawid Konotey-Ahulu have been deploying a fine blend of social, intellectual and financial capital to drive the consultant’s goal to help make 100m people financially secure. Read more...